New era of direct blood
oxygenation for respiratory support
INSPIRA directly oxygenates the blood, bypassing the lungs to provide respiratory support to patients
Augmented Respiration Technology preempts the need for Mechanical Ventilation (MV) which requires intubation and sedation
Advanced oxygenation for superior patient care
Millions are affected by acute respiratory distress (ARD)
Mechanical ventilation (MV) is one of the last resort interventions used to treat patients in intensive care units
Hospitals face dilemmas between saving a patient and exposing them to the high risks and complications associated with MV
Doctors seek a solution to treat patients whilst awake & mobile
Advanced oxygenation for superior patient care
Millions are affected by acute respiratory distress (ARD)
Mechanical ventilation (MV) is one of the last resort interventions used to treat patients in intensive care units
Hospitals face dilemmas between saving a patient and exposing them to the high risks and complications associated with MV
Doctors seek a solution to treat patients whilst awake & mobile
Dilemmas With Mechanical Ventilation
MV is a machine that artificially inflates the lungs with oxygenized gas, as a measure to save ARD patients
High Risks
1 in 2 patients die 2 in 5 suffer complications
MV Limited to ICU
Patient intubation & sedation requires highly specialized staff
Growing Costs
Hundreds of $billions in healthcare expenditure
Expensive
Current ICU costs of treatment may exceed US$ 10K per day
Stagnant
No innovative alternative developed in over 70 years
Probelm with intubation and MV
Mortality rate
Readmission (long-term physical health impairments)
Ventilator associated lung injury (VALI)
Ventilator associated pneumonia (VAP)
Of hospital days - weaning off MV
Respiratory muscle wasting & pressure wounds
Medically induced coma
* Statistics have been rounded
![]()
ART 500 Respiratory First Line Treatment
Treated patients
Are awake & mobile
Applicable
In most clinical settings Hospitals: ICU’s, ER’s, General Wards & Clinics
Ambulatory
Intensive Care Ambulances & Military
Competitive Advantage
Preempts MV (Patient Treated Awake)
Ambulatory & General Wards
ICU Applicable
Minimally Invasive (Not require radiography)
No blood thinners
Low risks & complications
Not require highly specialized staff
Weaning /Rehabilitation Risk
Weaning /Rehabilitation Risk
![]()
ART Benefits
- Expanding care to all hospital settings
- Emergency & ambulatory situations
- Rural hospitals & clinics
- Patients treated while awake & mobile
- Reduced patient risk in relation to MV
- No need for weaning
- Minimally invasive (No radiography)
- Reduced hospital days & costs
- Not require highly specialized staff
Accomplishments
PCT
Patents
IIA Grant Awarded
Pre-Clinical Studies
Investor Relations
News
Co-Founders
Experienced in respiratory medicine, clinical development and regulatory expertise in medical devices
Joe Hayon, MBA
Co-Founder | President & CFO
Former CFO, CIO and Corp Manager of Global Medical, EMS and Defense companies
Elscint (Formerly NASDAQ & TSE : ELT, CT technology acquired by Philips Electronics, NYSE : PHG, MRI technology acquired by GE, NYSE : GE)
Sanmina – Medical Division (NASDAQ: SANM)
Arazim Integrated Technologies Group
Plasan Group (Plasan Sasa, Plasan North America, Kazak, Plasan Carbon Composites
Dr. Udi Nussinovitch, MD PhD
Co-Founder | CMO
Cardiology Fellow with ICU experience, senior diving and hyperbaric physician
Sheba Medical Center, Israel Naval Medical Institute, Technion Institute of Technology, Meir Medical Center, Tel Aviv University
Publications Edited:
The Heart in Rheumatic, Autoimmune and Inflammatory Diseases, 2017.
Emerging Technologies for Heart Diseases, 2020.
Dagi Ben-Noon, BSc
Co-Founder | CEO
Multi industry experience in leading R&D activities & cultivating in-house innovation.
Highly experienced managing R&D, product design & development, system engineering & supply chain management
Former Co-Founder, COO and Director of Nano Dimension (NASDAQ : NNDM)
Executive Medical Board
Dr. Yigal Kasif, MD
Chief ECMO Advisor
Cardiac Surgeon & Director of ECMO Israel
Adult Cardiac Surgery, Heart Transplantation,
Assist Device & ECMO, Intensive Care Treatment
Sheba Tel Ha Shomer Hospital, Cambridge University, UCLA, Hebrew University of Jerusalem
Prof. Joseph Kost, D.Sc MBA
Chief Biomedical Advisor
Professor and Senior Advisor to the President on International Research Strategies,
Chair of Biomedical Engineering and past Dean of the Faculty of Engineering Sciences at Ben-Gurion University
Prof Eli Gabbay, MBBS MD FRACP
Chief Respiratory Advisor
Respiratory Physician
Professor of Medicine, School of Medicine, Fremantle, University of Notre Dame, Australia
Professor of Medicine, School of Medicine, University of Western Australia
Dr. Orit Cohen Jacob
Clinical & Research Consulting
Dr. Orit is a veterinary surgeon with a unique speciality in Laboratory animal science.
She has 23 years of experience in research, 16 years in IIBR – Israeli Prime minister’s office, founding and heading a large, state of the art, pre-clinical facility, in accordance with GMP/ GLP quality requirements (small and large animals).
Dr. Orit was the first women elected as chairwomen of the National Animal Experiments Ethics Committee, responsible for all regulations in Israel for animal lab experiments.
Subscribe for our newsletter updates
